The purpose of this study is to determine if the COXEN algorithm, using the diagnostic device Affymetrix GeneChip, is able to predict which chemotherapies will be best for treatment of recurrent or persistent ovarian, fallopian tube, or primary peritoneal cancer.
The current proposal seeks to apply and extend this novel genomic prediction technique to finding better chemotherapeutic options for recurrent ovarian cancer using individual patients' gene-expression signatures of chemosensitivity. The utility of the COXEN technique has been validated and found to accurately predict 1) the chemosensitivity of an independent panel of 40 bladder cancer cell lines; 2) activity of each of the \>45K candidate compounds in the NCI-60 drug screening database, which resulted in the identification of a highly-effective novel compound for bladder cancer and patients' responses and survival on 12 historical clinical trials of combination chemotherapy. In particular, the GEMs of breast cancer can be used to stratify both clinical response and overall patient survival with a striking difference between the predicted responders vs. predicted non-responders in 5 independent chemotherapeutic trials of breast cancer. The next step is to test the prediction model in recurrent ovarian cancer.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Masking
NONE
Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
overall response rate
patient will have CT scans and CA 125 drawn to track response to chemotherapy
Time frame: 12 months
overall survival
patient will be tracked for life
Time frame: subject lifetime
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.